Search for David Brennan and
    1. February 6, 2014

      Pascal wagers AstraZeneca’s replenished pipeline will deliver

      Pascal Soriot has half-justified his £4m signing-on bonus from AstraZeneca. Shares in the drugs group have risen about 26...

    2. October 15, 2013

      AstraZeneca experiments with Spirogen deal

      AstraZeneca, the Anglo-Swedish pharmaceutical group struggling to boost its pipeline of experimental medicines, is to pay at...

    1. July 15, 2013

      AstraZeneca chief financial officer set to move to BG Group

      Simon Lowth, chief financial officer at AstraZeneca, is set to join oil and gas company BG Group a year after he missed out...

    2. March 19, 2013

      Defensive AstraZeneca punts on Cambridge

      Karma is revenging itself on George Osborne. In last year’s budget he trumpeted news that GlaxoSmithKline would spend £500m...

    3. February 24, 2013

      Movers and shakers: February 25

      ● Baring Asset Management has named Angus Woolhouse global head of distribution. He replaces George Harvey, who will be...

    4. January 31, 2013

      AstraZeneca warns of tough year ahead

      AstraZeneca’s new chief executive expressed openness to large, “disruptive” acquisitions, while stressing his primary focus...

    5. January 15, 2013

      AstraZeneca’s new chief shakes up top team

      AstraZeneca’s new chief executive has replaced the company’s head of research and development and the top commercial...

    6. December 16, 2012

      Asset management pay a frosty issue

      Spring may be a distant memory but the large-scale revolt over boardroom pay, which gathered steam in April and was...

    7. December 12, 2012

      Little room to envy Brooks’ £10.9m payout

      Unusually for a top executive, Rebekah Brooks appears to be benefiting from pay inflation long after she left her job. When...

    8. October 29, 2012

      AstraZeneca’s Soriot awarded £11m package

      The new chief executive of AstraZeneca will receive up to £11m for his first year’s work, including £5m in shares in the...

    9. October 25, 2012

      AstraZeneca looks to deals for boost

      AstraZeneca, the Anglo-Swedish pharmaceuticals group struggling to boost investor confidence as it loses patents on leading...

    10. October 2, 2012

      AstraZeneca’s new chief suspends buybacks

      AstraZeneca’s new chief executive asserted his authority on his first day in the job by suspending share buybacks for the...

    11. August 31, 2012

      New brooms sweep into the boardroom

      Two of the hottest seats in the UK boardroom were filled this week. Pascal Soriot, vet-turned-Roche-executive, was named the...

    12. August 28, 2012

      Roche executive named AstraZeneca chief

      AstraZeneca has poached a top executive from Roche to head the Anglo-Swedish pharmaceutical company as it seeks fresh deals...

    13. July 16, 2012

      Ex-AstraZeneca chief given £4.5m payout

      The former chief executive of AstraZeneca has been awarded a severance package worth as much as £4.5m following his ousting...

    14. July 2, 2012

      Deal boosts AstraZeneca’s interim chief

      The $7bn planned acquisition of Amylin announced this weekend is an indicator of interest in the fast-growing diabetes...

    15. June 11, 2012

      Anger as business chiefs’ pay soars 10%

      The row over rising executive pay has been reignited by a survey showing the median total remuneration of FTSE 100 bosses...

    16. May 31, 2012

      AstraZeneca prepares for upheaval

      The new chairman of AstraZeneca says his top priority is finding a permanent chief executive for the troubled Anglo-Swedish...

    17. May 24, 2012

      BT chief rings up £7.7m in cash-and-shares pay

      Ian Livingston, chief executive of BT Group, took home £7.7m of cash and shares over the past year, making him one of the...

    18. May 20, 2012

      AstraZeneca in experimental drugs push

      AstraZeneca plans to seal several new deals this year to fill its flagging pipeline of experimental medicines, which may be...

    19. May 15, 2012

      AstraZeneca among suitors eyeing Amylin

      Amylin Pharmaceuticals, the US maker of diabetes-focused medicines, has attracted a string of potential suitors, including...

    20. May 11, 2012

      Witty targets HGS with first hostile bid

      Henry Wellcome, the US immigrant who laid the foundations 130 years ago for the UK-based pharmaceutical group...

    21. May 8, 2012

      Shareholders stir

      What took them so long? Investors have belatedly wakened from their apathetic slumber. They, after all, are the ones who...

    22. May 8, 2012

      Moss quits after pay revolt at Aviva

      Investors angry about a mismatch between executive pay and corporate performance claimed their third scalp on Tuesday as...

    23. May 6, 2012

      Pharma tries to avoid falling off ‘patent cliff’

      For four years Chris Viehbacher has been bracing himself for a nasty turn. Since being appointed Sanofi’s chief executive in...

    24. May 3, 2012

      Sly Bailey to leave Trinity Mirror

      Sly Bailey, the chief executive of Trinity Mirror who was facing a shareholder revolt about her £1.7m pay package,...

    25. May 2, 2012

      Pharma needs an injection of financial engineering

      “You’re going to need a bigger boat,” says the police chief played by Roy Scheider in the film Jaws, when he first catches...

    26. FT Alphaville

      April 30, 2012

      Weekend news catch-up

      Weekend headlines from the FT and other UK media:* From The FT, -       The pound has become an unlikely haven in Europe. It...

    27. April 27, 2012

      Angry investors must face bigger questions

      It is annual meeting season in the UK, when shareholders gather to eat free biscuits and listen to board members...

    28. April 27, 2012

      AstraZeneca needs new chief and new strategy

      No one disagrees on the cause of AstraZeneca’s current financial malaise. The problem – as David Brennan, the chief...

    29. April 26, 2012

      AstraZeneca: quest for a cure

      Ignominious exits are fast becoming a trend – think Silvio Berlusconi and James Murdoch, to mention a couple. David...

    30. April 26, 2012

      Brennan’s departure opens door to change

      For a chief executive who said he had been thinking about the decision to step down for “a while”, David Brennan sounded...

    31. April 26, 2012

      Simon Lowth, interim CEO AstraZeneca

      Simon Lowth’s appointment as interim chief executive of AstraZeneca puts him in a strong position as the long-term successor...

    32. April 26, 2012

      AstraZeneca chief Brennan to retire early

      AstraZeneca is facing fresh pressure from investors seeking a further board shake-and a change in the strategic direction of...

    33. April 23, 2012

      Gout firm cure for AstraZeneca afflictions

      Gout was historically associated with overindulged dandies who were past their prime. So it is apt that AstraZeneca, a...

    34. April 23, 2012

      AstraZeneca to pay $1.3bn for Ardea

      AstraZeneca is set to acquire US biotechnology company Ardea Biosciences in a $1.3bn deal, as the Anglo-Swedish...

    35. April 22, 2012

      Pressure grows for AstraZeneca

      David Brennan, the chief executive of AstraZeneca, faces a vote for re-election to the board of the Anglo-Swedish...

    36. April 13, 2012

      BP investors in mini-rebellion over pay

      Shareholders in BP staged a mini-rebellion over executive pay this week, amid widespread frustration with a company that is...

    37. April 10, 2012

      AstraZeneca

      The noise at AstraZeneca is the sound of knives being sharpened. The London-listed pharmaceuticals group’s shareholders are...

    38. April 9, 2012

      AstraZeneca chief in need of a tonic

      When David Brennan won the race to become chief executive of AstraZeneca six years ago, he joked to a colleague who had come...

    Search for David Brennan and